DelveInsight, a leading market research and healthcare consulting company, has released its latest report, “Glucagon-like Peptide-1 (GLP-1) Agonists Market Size, Target Population, Competitive Landscape & Market Forecast – 2036.” The report provides a comprehensive assessment of GLP-1 agonists, including target patient population, market size forecasts, competitive landscape, emerging therapies, reimbursement trends, and market dynamics across the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

Key Takeaways from the GLP-1 Agonists Market

• The GLP-1 Agonists Market across the 7MM is anticipated to grow significantly during the forecast period 2022–2036.

• DelveInsight estimates that the GLP-1 Agonists Market Size will increase from approximately USD 50 billion in 2022 to nearly USD 114.5 billion by 2036 across the 7MM.

• In December 2024, Eli Lilly’s MOUNJARO/ZEPBOUND became the first GLP-1–based therapy approved for obstructive sleep apnea (OSA), expanding the therapeutic reach of GLP-1 agonists into a new disease area.

• In December 2025, the FDA approved oral WEGOVY (semaglutide) as the first oral GLP-1 receptor agonist for chronic weight management in adults with obesity or overweight.

• The GLP-1 agonist pipeline includes promising candidates such as Retatrutide and Orforglipron from Eli Lilly, Efinopegdutide from Merck, and CagriSema from Novo Nordisk.

• Obesity represents the largest target population among key indications eligible for GLP-1 agonist therapy, with approximately 120 million prevalent cases in the United States in 2025.

• Type 2 diabetes accounted for approximately 32 million prevalent cases in the United States in 2025, while OSA accounted for approximately 82 million prevalent cases.

• Leading GLP-1 agonist companies including Eli Lilly, Novo Nordisk, Boehringer Ingelheim, Merck, Roche, and Regor Therapeutics are actively advancing innovative therapies to strengthen the future GLP-1 market landscape.

• Emerging therapies such as Retatrutide, CagriSema, Survodutide, and Efinopegdutide are expected to drive the next wave of market expansion.

Keen to know more about the market? Request our sample page for the GLP-1 Agonists Market.

https://www.delveinsight.com/sample-request/glucagon-like-peptide1-glp1-agonists-market-forecast

Key Factors Driving the GLP-1 Agonists Market

Rising Prevalence of Obesity and Type 2 Diabetes

The growing global burden of obesity and type 2 diabetes continues to expand the eligible treatment population for GLP-1 agonists. Type 2 diabetes accounts for more than 85% of all diabetes cases worldwide, while obesity prevalence continues to rise across major markets, creating sustained demand for effective metabolic therapies.

Expanding Clinical Utility Across Multiple Indications

GLP-1 agonists have evolved beyond glycemic control and are increasingly utilized for obesity, cardiovascular risk reduction, and obstructive sleep apnea. Ongoing research is also exploring their potential role in MASH, non-alcoholic fatty liver disease, polycystic ovary syndrome, depression, and other metabolic disorders.

Strong Innovation in Next-Generation Incretin Therapies

The development of dual- and triple-receptor agonists, including GIP/GLP-1 and GCGR/GLP-1 combinations, is expected to significantly improve efficacy outcomes and reshape the competitive landscape. These innovations represent some of the most important trends driving future GLP-1 market growth.

GLP-1 Agonists Competitive Landscape

The current GLP-1 agonist market is dominated by therapies such as OZEMPIC/RYBELSUS/WEGOVY (semaglutide) from Novo Nordisk and MOUNJARO/ZEPBOUND (tirzepatide) from Eli Lilly. These therapies have demonstrated strong efficacy in glycemic control, weight management, and cardiovascular risk reduction.

Among emerging therapies, Retatrutide from Eli Lilly is one of the most promising candidates. The therapy acts as a triple agonist targeting GIP, GLP-1, and glucagon receptors and is currently in Phase III development for obesity, type 2 diabetes, osteoarthritis, and obstructive sleep apnea.

CagriSema, developed by Novo Nordisk, combines cagrilintide with semaglutide in a once-weekly fixed-dose formulation and has demonstrated substantial weight-loss potential in Phase III trials. Survodutide, a GCGR/GLP-1 dual agonist from Boehringer Ingelheim, is also advancing through Phase III development and has received Breakthrough Therapy designation for MASH.

These developments are expected to significantly influence future GLP-1 Agonists Market Share and strengthen the overall market outlook.

Discover more about therapies set to grab major GLP-1 Agonists market share @ GLP-1 Agonists Treatment LandscapeRecent Developments in the GLP-1 Agonists Market

• In December 2025, Novo Nordisk submitted an NDA to the FDA for CagriSema for chronic weight management in adults with obesity or overweight and weight-related comorbidities.

• In December 2025, Eli Lilly announced positive topline results from the Phase III TRIUMPH-4 trial of Retatrutide in adults with obesity and knee osteoarthritis, achieving up to 28.7% mean weight loss at 68 weeks.

• In October 2024, the FDA granted Breakthrough Therapy designation to Survodutide for adults with non-cirrhotic MASH and moderate-to-advanced fibrosis.

• In January 2026, the FDA requested the removal of suicide-related warnings from the labels of leading GLP-1 therapies after a comprehensive safety review found no clear evidence of increased psychiatric risk.

• Beginning in mid-2026, Medicare is expected to initiate coverage of certain GLP-1 therapies for eligible patient populations following pricing agreements with major manufacturers.

What are GLP-1 Agonists?

Glucagon-like peptide-1 (GLP-1) agonists are a class of therapeutics that mimic the action of the endogenous GLP-1 hormone, helping regulate glucose metabolism and appetite. These therapies stimulate insulin secretion, suppress glucagon release, delay gastric emptying, reduce food intake, and improve glycemic control. GLP-1 agonists are widely used for type 2 diabetes, obesity, and other metabolic disorders, with expanding applications across multiple disease areas.

GLP-1 Agonists Epidemiology Segmentation

The GLP-1 agonists target population analysis provides insights into eligible patients across major indications and markets. The report evaluates:

• Total Prevalent Cases of Selected Indications

• Total Diagnosed Cases of Selected Indications

• Patient Seeking Help for Selected Indications

• Treated Cases with GLP-1 Agonists

• Country-specific Patient Population Trends

• Indication-specific Eligible Patient Population

Scope of the GLP-1 Agonists Market Report

• Therapeutic Assessment: Current and emerging GLP-1 agonist therapies

• GLP-1 Agonists Market Dynamics: Key market assumptions, uptake patterns, and forecast trends

• Key Companies: Eli Lilly, Novo Nordisk, Boehringer Ingelheim, Merck, Roche, Regor Therapeutics, and others

• Key Therapies: Semaglutide, Tirzepatide, Retatrutide, CagriSema, Survodutide, Efinopegdutide, and others

• Competitive Intelligence Analysis: Market positioning and therapy comparison

• KOL Perspectives, Market Access, Pricing Trends, and Reimbursement Assessment

To know more about GLP-1 agonist companies working in the market, visit @ GLP-1 Agonists Competitive LandscapeTable of Contents

1. GLP-1 Agonists Market Report Introduction
2. Executive Summary
3. SWOT Analysis
4. GLP-1 Agonists Market Share Overview
5. GLP-1 Agonists Market Overview
6. Background and Overview
7. Epidemiology and Patient Population
8. Country-Specific Patient Population
9. Current Treatment Practices
10. Emerging Therapies
11. Competitive Landscape
12. Market Outlook
13. Country-Wise Market Analysis (2022–2036)
14. Market Access and Reimbursement
15. Market Drivers
16. Market Barriers
17. Appendix
18. Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kirti Sharma
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/